Drugs / SYH2085
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07412353 | Jan → Nov 2026 expected | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗
The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the SYH2085 tablets (the ‘‘Product ’’) developed by the Group have obtained approval from the Nati onal Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-07 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2085 TABLETS FOR THE TREATMENT OF UNCOMPLICATED INFLUENZA IN ADULTS OFFICIALLY INITIATED IN CHINA irasia.com ↗ |
| 2025-12-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2085 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412353 ↗ |
| Route | Oral | “single oral administration of SYH2085 tablet on Day 1” NCT07412353 ↗ |